Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
A Phase 1 Study of Amrubicin in Combination With Lenalidomide and Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Sponsor: Celgene Corporation
Listed as NCT01355705, this PHASE1/PHASE2 trial focuses on Multiple Myeloma and remains completed. Sponsored by Celgene Corporation, it has been updated 12 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 7 earlier versions
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jul 2018 — Oct 2018 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene Corporation
- Michaela Liedtke
For direct contact, visit the study record on ClinicalTrials.gov .